Approximately 65% for general side effects
Approximately 70% for side effects at the injection site

**METHODS**

**Participants:** 14,645 participants in Phase III, observer-blind, placebo-controlled multicenter trials (RZV; N=7,695), Placebo (N=7,710)

**Vaccination schedule:**
- Month 0: RZV (N=6,950), Placebo (N=6,950)
- Month 2: RZV (N=6,950), Placebo (N=6,950)

**Randomization:** 1:1

**VACCINATION MEDIAN SAFETY FOLLOW-UP:** 4.4 years

**For this post-hoc analysis, ZOE-50 and ZOE-70 data from participants having completed the diary cards for both RZV doses were pooled (TVC reactogenicity sub-cohort).**

**RESULTS**

- **Highest pain**
  - Grade 3: 406 (39%, 84% of participants who reported pain at any intensity)
  - Grade 2: 141 (40.8%, 23.2% of participants who reported pain at any intensity)
  - Grade 1: 74 (8%, 1.3% of participants who reported pain at any intensity)
  - Grade 0: 1,043 (72.6%, 1.9% of participants who reported pain at any intensity)

- **Highest pain at the injection site**
  - Grade 3: 136 (13.6%, 8.5% of participants who reported pain at any intensity)
  - Grade 2: 90 (9%, 1.3% of participants who reported pain at any intensity)
  - Grade 1: 50 (5%, 0.8% of participants who reported pain at any intensity)
  - Grade 0: 1,235 (72.6%, 2.1% of participants who reported pain at any intensity)

- **Injection site swelling**
  - Grade 3: 67 (6.4%, 0.8% of participants who reported swelling at any intensity)
  - Grade 2: 244 (23.7%, 3.5% of participants who reported swelling at any intensity)
  - Grade 1: 1,395 (76%, 22.4% of participants who reported swelling at any intensity)
  - Grade 0: 2,893 (81.6%, 49.5% of participants who reported swelling at any intensity)

- **Injection site redness**
  - Grade 3: 103 (1.4%, 0.1% of participants who reported redness at any intensity)
  - Grade 2: 412 (53.5%, 7.4% of participants who reported redness at any intensity)
  - Grade 1: 700 (9.0%, 1.1% of participants who reported redness at any intensity)
  - Grade 0: 4,000 (56.9%, 7.0% of participants who reported redness at any intensity)

- **Arms and shoulders**
  - Grade 3: 422 (53.5%, 7.4% of participants who reported pain at any intensity)
  - Grade 2: 195 (24.3%, 3.5% of participants who reported pain at any intensity)
  - Grade 1: 443 (54.8%, 7.6% of participants who reported pain at any intensity)
  - Grade 0: 1,013 (72.6%, 13.5% of participants who reported pain at any intensity)

- **Legs**
  - Grade 3: 9 (0.1%, 0.1% of participants who reported pain at any intensity)
  - Grade 2: 21 (25.0%, 0.3% of participants who reported pain at any intensity)
  - Grade 1: 21 (25.0%, 0.3% of participants who reported pain at any intensity)
  - Grade 0: 80 (1.0%, 0.1% of participants who reported pain at any intensity)

- **General events**
  - Grade 3: 21 (25.0%, 0.3% of participants who reported pain at any intensity)
  - Grade 2: 21 (25.0%, 0.3% of participants who reported pain at any intensity)
  - Grade 1: 21 (25.0%, 0.3% of participants who reported pain at any intensity)
  - Grade 0: 21 (25.0%, 0.3% of participants who reported pain at any intensity)

**What is new?**

**CONCLUSIONS**

- Vaccines who did not experience a specific AE after dose 1, generally did not experience the same event after dose 2.
- Vaccines who reported Grade 3 specific AEs after dose 7 were more likely to report the same AE at any intensity after dose 2.

**PLAIN LANGUAGE SUMMARY**

- Vaccines who did not experience a specific AE after dose 1, generally did not experience the same event after dose 2.
- Vaccines who reported Grade 3 specific AEs after dose 7 were more likely to report the same AE at any intensity after dose 2.

**ACKNOWLEDGMENTS**

***

**REFERENCES**

*Joon Hyung Kim MD, 20850

**Contact:**

*Research and Development, Seqirus, Parkville, Victoria, Australia; CureVac AG, Tübingen, Germany

**Supplementary Material:**

*Supplemental Table S1: reactogenicity events from RZV and placebo groups (pooled TVC)